OXA-163 producing *Klebsiella pneumoniae* in Cairo, Egypt, 2009-2010

Mohammed O. Abdelaziz,1 Celestino Bonura,2 Aurora Aleo,2 Ramadan A. El-Domany,1 Teresa Fasciana,2 and Caterina Mammina2*

Department of Microbiology and Immunology, Faculty of Pharmacy, Helwan University, Cairo, Egypt1; Department of Sciences for Health Promotion “G. D’Alessandro”, University of Palermo, Palermo, Italy2

Running title: *K. pneumoniae* producing OXA-163 in Egypt

Keywords: OXA-163, carbapenemase, *Klebsiella pneumoniae*, antimicrobial drug resistance,

* Corresponding author

Caterina Mammina, M.D.
Department of Sciences for Health Promotion "G. D'Alessandro"
Via del Vespro 133
I-90127 Palermo, Italy
phone +39 0916553623
FAX +39 0916553641
email caterina.mammina@unipa.it

1

Copyright © 2012, American Society for Microbiology. All Rights Reserved.

JCM Accepts, published online ahead of print on 18 April 2012

Downloaded from http://jcm.asm.org on June 23, 2017 by guest
Abstract

Two genetically unrelated OXA-163 carrying *Klebsiella pneumoniae* strains were identified from two infection cases in June 2009 and May 2010 in Cairo, Egypt. OXA-163 producing *Enterobacteriaceae* had been previously reported in Argentina only. Both patients had no history of travel abroad. The emergence of this newly recognized OXA-48 related β-lactamase able to hydrolyze cephalosporins and carbapenems is especially worrying in a geographic area where OXA-48 is endemic and effective surveillance for antibiotic resistance is largely unaffordable.
Carbapenems are first-line drugs for severe infections caused by extended spectrum β-lactamase (ESBL) producing Enterobacteriaceae. However, the emergence and rapid diffusion of carbapenemase-producing Gram negatives in the recent years is compromising the therapeutic efficacy of this class of antimicrobial drugs (2,11,16).

Recently, two blaOXA-163 producing isolates of Klebsiella pneumoniae and Enterobacter cloacae have been identified in Argentina (15). OXA-163 differs from OXA-48 by a single aminoacid substitution and a 4-aminoacid deletion only, but it works as an extended-spectrum oxacillinase showing a weaker ability to hydrolyze carbapenems than OXA-48, but a concurrent significant ability to hydrolyze extended-spectrum cephalosporins (15). The blaOXA-163 gene has been putatively proposed as the equivalent in south America of the blaOXA-48 gene, that is increasingly identified in the southern and eastern Mediterranean countries (1,6,8,14).

Here, we report two autochthonous cases of infection caused by two genetically unrelated OXA-163 carrying K. pneumoniae strains in Cairo, Egypt, in 2009 and 2010.

Case 1 was a 31 year-old woman hospitalized in Cairo (Egypt) on June 5, 2009 due to acute myelocytic leukemia. She was on therapy by doxorubicin and cytarabine. After 16 days since admission, she was transferred to an intensive care unit because of heart and respiratory failure.

Initial antibiotic therapy was started with vancomycin, azithromycin and imipenem. Blood culture was positive for a carbapenem-resistant strain of K. pneumoniae (isolate 18). The patient died on June 23.

Case 2 was a 25 year-old man with an 18-month history of acute lymphocytic leukemia. He was in outpatient follow-up until May 2010, when he was admitted to hospital due to a lower respiratory tract infection. He was started on cefepime and amikacin on May 14, but the clinical course was complicated. A sputum culture grew carbapenem-resistant K. pneumoniae (isolate 78). No further data about the treatment outcome were available for this patient.

Both patients had never traveled outside of Egypt.
The two carbapenem resistant *K. pneumoniae* strains were sent to the molecular epidemiology laboratory of the Department of Sciences for Health Promotion “G. D’Alessandro”, University of Palermo, Italy, for confirmation and typing. The two isolates were initially tested for antimicrobial susceptibility by disk diffusion according to the Clinical and Laboratory Standards Institute (CLSI) guidelines (3). Susceptibility testing for third generation cephalosporins and carbapenems was performed with Etest strips (BioMérieux, Marnes-La-Coquette, France). Results were interpreted according with the CLSI interpretative criteria (3).

Polymerase chain reaction (PCR) screening for carbapenemase encoding genes of classes A (*bla*KPC, *bla*GES), B (*bla*VIM, *bla*IMP), and D (*bla*OXA-48) and for ESBL encoding genes *bla*TEM, *bla*OXA, *bla*SHV, *blaCTX-M* was performed as described previously (4). PCR products were purified and sequenced using the BigDye Terminator v1.1 Cycle Sequencing kit (Applied Biosystems Warrington, UK) and the ABI Prism 310 Genetic Analyzer (Applied Biosystems, Foster City, Calif, US). The nucleotide and deduced protein sequences were analyzed with the software available from the National Center for Biotechnology Information web site (www.ncbi.nlm.nih.gov). Outer membrane protein (OMP) gene amplification was conducted using *ompK35*-F and -R and *ompK36*-F and -R and PCR products were sequenced using OMP primers according with Kaczmarek et al. (8). The sequences were analyzed by comparison with reported nucleotide sequences in GenBank. Expression levels of the *ompK35* and *ompK36* genes were not investigated.

To evaluate their clonal relationship, the two *K. pneumoniae* isolates were submitted to pulsed field gel electrophoresis (PFGE) after *XbaI* DNA digestion. Strain differentiation by PFGE was based on the criteria of Tenover et al. (17). The Rep-PCR DiversiLab Microbial Typing System® (bioMérieux, Marcy l’Étoile, France) was also used with the DiversiLab *Klebsiella* kit. DNA fragment separation and detection were done using the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) and results were analyzed and interpreted using the Kullback–Leibler method, as previously reported (13). Moreover, multilocus sequence typing (MLST) was performed on both isolates according with the protocol described on the *K.*
pneumoniae MLST website (http://www.pasteur.fr/recherche/genopole/ PF8/mlst/). MLST results were compared with the international *K. pneumoniae* MLST database at the Pasteur Institute in Paris, France.

The two *K. pneumoniae* isolates exhibited resistance to extended-spectrum cephalosporins (cefotaxime, ceftazidime, cefepime), aztreonam and to carbapenems (meropenem and imipenem) (Table 1). Additionally, both isolates were resistant to ciprofloxacin and gentamicin and susceptible to colistin.

For both isolates, positive PCR results were obtained for the *bla*<sub>TEM</sub>, *bla*<sub>SHV</sub> and *bla*<sub>CTX-M</sub> genes and sequencing identified the narrow-spectrum β-lactamase genes TEM-1 and SHV-1 and the ESBL CTX-M-15. A *bla*<sub>OXA-48</sub>-like gene was detected by PCR in both isolates that, by sequencing, was identified as *bla*<sub>OXA-163</sub> (www.lahey.org).

The *ompK35* and *ompK36* genes of isolates 18 and 78 were amplified, sequenced and aligned with those of OMP gene sequences of *K. pneumoniae* MGH 78578. The *ompK35* gene of both isolates showed a frameshift mutation due to a nucleotide deletion at nt.873. Moreover, in the *ompK35* gene of the isolate 18, sequencing revealed one substitution T → A at nucleotide (nt.) position 108, generating a TAA nonsense mutation which resulted in a premature stop codon at aminoacid position 36. Silent point mutations were also found at nt. 303, 420, 537, 648 and 786 on the nucleotide sequence of both isolates. Comparing the *ompK36* gene sequences with the wild-type sequence, both revealed an insertion of six nucleotides (5′-GGCGAC-3′) at nt. positions 405 - 410, due to a duplication of the adjacent region at nt. positions 399 to 404. Sequencing of the *ompK36* sequence of the isolate 78 detected also a 9-nucleotide deletion at nt. positions 556-564. The *ompK35* of the isolate 78 was assigned accession number JQ660370 and the *ompK36* sequences of the isolates 18 and 78 were assigned accession numbers JQ660371 and JQ660372, respectively, in the GenBank database.
PFGE and rep-PCR showed that the two isolates were genetically unrelated to each other (Fig. 1). Additionally, MLST attributed two different sequence types (STs) 37 and 20, respectively, to the strains 18 and 78. The main characteristics of the two isolates of *K. pneumoniae* are summarized in Table 1. The findings of this study are of concern for a number of reasons. First, the detection of OXA-163 outside the continent where it has been firstly identified was unexpected. This finding seems to stand against the hypothesis of OXA-163 as the equivalent in South America of OXA-48 in the Mediterranean area (15). The two patients had no history of travel abroad. Moreover, possible contacts with source patients from Argentina, though it was not possible to investigate them in detail, appear to be unlikely due also to the one-year long interval of time between the two cases. An autochthonous emergence in Egypt of the OXA-163 resistance determinant appears to be the more plausible explanation. Second, the two *K. pneumoniae* isolates were genetically unrelated based upon PFGE and MLST. This rules out the clonal expansion of an OXA-163 producing strain in Egypt and, alternatively, supports the hypothesis of horizontal transmission of this genetic determinant via plasmids, according with the previous report (14). Notably, strains belonging to STs 20 and 37 have been previously identified in different countries as ESBL or carbapenemase producers (11,12). Moreover, it is of special interest that OXA-163 has been identified in Egypt, a country of North Africa, a geographical area considered as endemic for OXA-48 producing Gram negatives (6,9,10). Third, both strains had much higher MICs for carbapenems than those reported by Poirel et al. (15). Studies suggest that outer membrane permeability defects coupled with ESBL production can confer resistance to carbapenems (5,9). This is likely to account for the higher level of carbapenem resistance detected in our strains. It is also noteworthy that the presence of similar mutations altering the properties of the OmpK35 and 36 porins have been previously described in an ST37 *K. pneumoniae* clone carrying *bla*CTX-M-15 and exhibiting reduced susceptibility to carbapenems (5). However, our study did not definitively attribute the carbapenem resistance
phenotype to OXA-163, because transfer of antimicrobial agent resistance experiments and plasmid
analysis were not performed. This is a substantial limitation of our report.

As previously reported about OXA-163 producing strains in Argentina, because of its unique
hydrolysis ability mimicking a class A ESBL, OXA-163 could be able to spread unrecognized as a
carbapenemase (15). Surveillance of emergence and dissemination of enterobacteria with complex
carbapenem resistance mechanisms is a serious public health problem where the costs can be
unaffordable, such as low-resource countries. Further studies are urgently needed to assess
prevalence of the blaOXA-163 genetic determinant worldwide.
REFERENCES

detection of oxacillinase-mediated resistance to carbapenems in *Klebsiella pneumoniae* from

2. Carmeli, Y., et al. 2010. Controlling the spread of carbapenemase-producing Gram-

antimicrobial susceptibility testing; 21th informational supplement. CLSI M100-
S21. Clinical and Laboratory Standards Institute, Wayne, PA.

of multiplex PCR assays for the detection of genes encoding important beta-lactamases in

54:4178-4184.

encoded OXA-48 carbapenemase in *Escherichia coli* from Israel. J. Antimicrob.
Chemother. 66:672–673.

resistance to ertapenem and other β-lactams in *Klebsiella pneumoniae*. Antimicrob. Agents
Chemother. 48:3203-3206.

resistance in a *Klebsiella pneumoniae* clinical isolate is due to the combination of *bla*\textsubscript{ACT}-1 β-
lactamase production, porin OmpK35/36 insertional inactivation, and down-regulation of


Legend to Figure

XbaI- Pulsed field gel electrophoresis patterns and rep-PCR patterns of two OXA-163 carrying *Klebsiella pneumoniae* strains, Cairo, Egypt, 2009 and 2010.

A. Lanes: MW, *XbaI* digested DNA of *Salmonella* Braenderup H9812; 1, *K. pneumoniae* strain 18; 2, *K. pneumoniae* strain 78

Table 1. Main characteristics of two OXA-163 producing *K. pneumoniae* isolates detected in Egypt, June 2009 and May 2010

<table>
<thead>
<tr>
<th><em>K. pneumoniae</em> strain (patient)</th>
<th>MICs (µg/ml)*</th>
<th>bla genes</th>
<th>Sequence type</th>
</tr>
</thead>
<tbody>
<tr>
<td>18 (case 1)</td>
<td>&gt;256</td>
<td>TEM-1, SHV-1, CTX-M15, OXA-163</td>
<td>37</td>
</tr>
<tr>
<td>78 (case 2)</td>
<td>&gt;256</td>
<td>TEM-1, SHV-1, CTX-M15, OXA-163</td>
<td>20</td>
</tr>
</tbody>
</table>

* MICs assessed by Etest